Caption Management’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-300,800
Closed -$1.73M 1399
2025
Q1
$1.73M Sell
300,800
-98,800
-25% -$584K 0.02% 736
2024
Q4
$1.99M Buy
+399,600
New +$2.05M 0.02% 689
2022
Q2
Sell
-190,000
Closed -$846K 1405
2022
Q1
$846K Buy
190,000
+51,400
+37% +$205K 0.01% 1026
2021
Q4
$555K Buy
138,600
+25,200
+22% +$192K 0.01% 1226
2021
Q3
$996K Buy
+113,400
New +$1.04M 0.01% 1019

Other funds holding ALDX

Caption Management's ALDX Position: Q1 2026 in Review

Caption Management increased its Aldeyra Therapeutics (ALDX) stake by 371% in Q1 2026, buying an estimated $570K and bringing the position to 165,000 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Caption Management first reported a position in ALDX in Q3 2021 and has held it in 7 quarters since. The position peaked at $1.98M in Q4 2024. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Caption Management held 165,000 shares of Aldeyra Therapeutics worth $279K as of Q1 2026.
  • Caption Management bought 130,000 Aldeyra Therapeutics shares in Q1 2026, an estimated $570K.
  • Aldeyra Therapeutics made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1304 holding.
  • Caption Management first reported a position in Aldeyra Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • Caption Management's Aldeyra Therapeutics position peaked at $1.98M in Q4 2024.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.